Is pembrolizumab a biologic?

Is pembrolizumab considered a biologic?

Yes. Pembrolizumab (Keytruda) is classified as a biologic medicine. It is a monoclonal antibody produced using biological processes rather than being manufactured as a small-molecule chemical drug.

Why does it count as a biologic (and not a typical “small-molecule” drug)?

Pembrolizumab is an antibody therapy, meaning it’s designed as a protein-based treatment. Because it is made from biological systems (and not synthesized as a small molecule), it falls under the biologics category.

What does this mean for patients and prescribing?

Because it’s a biologic monoclonal antibody, pembrolizumab is typically administered as an IV infusion under oncology/immune-oncology treatment protocols (rather than as a standard oral small-molecule medication).

Patents and coverage context

For background on pembrolizumab’s drug and patent landscape, DrugPatentWatch.com tracks related filings and exclusivity information: https://www.drugpatentwatch.com/

Sources
1. DrugPatentWatch.com – pembrolizumab (Keytruda) patent information